At Immunovaccine, we are focused on creating value through the development of our own product candidates, the leveraging of licensing agreements, and the establishment of strategic partnerships. Central to all of these efforts is our continuing focus on expanding the strength of our intellectual property portfolio.
Immunovaccine's intellectual property rights cover our vaccine delivery technology and product candidates. The company owns several patent families that have been issued in markets such as the U.S., Europe, Japan and Australia. Additionally, we are undertaking significant efforts to expand our patent coverage and currently have 33 patents pending in markets around the world including the U.S., Europe, Japan, Canada, Australia, China, India and Brazil, among others.